Jobaaj Stories- 23 Apr 2025
Lupin Rises on US Launch of Kidney Drug Tolvaptan; $200 Million Revenue Target by FY26
Lupin Ltd. shares gained traction on Wednesday, rising 2.5% after the company announced the launch o
Explore Topics
Newsletter
Tag Clouds